Read time: 1 minute.
Patient enrollment in biomarker-selected lung cancer clinical trials may be constrained by the availability and timing of appropriate biomarker testing to determine eligibility, which can impose delays and undue burden on patients.

A timely analysis conducted by LUNGevity reveals that current biomarker testing requirements for enrollment in recent lung cancer clinical trials do not reflect patient preferences. A majority of patients/caregivers surveyed would at least pause and weigh alternative options to trial enrollment when faced with delays due to biomarker testing. However, a large proportion of recent lung cancer clinical trials required central biomarker testing for enrollment, and those accepting local biomarker testing still required additional testing or processing.
The data were presented at the 2026 ASCO Quality Care Symposium in Boston. The results of this analysis underscore a need for innovative policy solutions to support more flexible biomarker testing requirements.
Part 2 of LUNGevity’s Transforming Clinical Trials Initiative (TCTI) Annual Regulatory Series in December will focus on this issue, with discussions between regulators, trial sponsors, clinicians, and patients/advocates directed at understanding barriers to the use of more flexible biomarker testing requirements in clinical trials and how they can be resolved.
